Published in Blood Weekly, July 27th, 1998
The trial program, known as post-exposure prophylaxis (PEP), is aimed at people who have had unsafe sex or needle-sharing with an HIV infected partner. Although the program provides anti-HIV drugs, it is intended as a risk reduction program and not as a medical intervention.
"If we get people in who are very scared after a high-risk exposure, this is a very good opportunity for counseling interventions,"...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.